Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Immediate Effect of Taping on Foot Biomechanics in Patients With Hallux Valgus

NCT07409974 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-02-15
Last updated
2026-02-13

Condition(s) studied

Hallux Valgus

Investigational drug(s) / intervention(s)

rigit tapingkinesiologic taping

rigit taping: rigit taping technique

kinesiologic taping: kinesiologic taping technique

Study summary

The goal of this clinical trial is to comparatively investigate the immediate effects of rigid taping and kinesiological taping applications on foot biomechanics in patients with hallux valgus (HV). The main questions it aims to answer are:

Which taping approach (rigid or kinesiology) produces the most effective and fastest treatment response in the management of hallux valgus?

Researchers will compare two taping methods to investigate which method offers a more effective and faster treatment response in terms of foot biomechanics.

Participants will:

1. Individuals aged 18-65 years
2. Individuals with mild to moderate HV in one or both feet
3. HV patients who do not require/are not suitable for surgery or who refuse surgery and are referred/apply for conservative treatment
4. Individuals who have not engaged in any strenuous exercise or activity (such as running, walking, weight or resistance training, yoga, pilates, aerobics, step, etc.) in the last 2 days before evaluation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Individuals aged 18-65 years 2. Individuals with mild to moderate HV in one or both feet 3. HV patients who do not require/are not suitable for surgery or who refuse surgery and are referred/apply for conservative treatment 4. Individuals who have not engaged in any strenuous exercise or activity (such as running, walking, weight or resistance training, yoga, pilates, aerobics, step, etc.) in the last 2 days before evaluation. Exclusion Criteria: 1. The presence of contraindications for the use of the tapes (skin lesions, wounds, fungal infections, allergic reactions, sensory loss, etc.). 2. Diagnosis of diabetic foot. 3. Complete loss of hallux mobility, presence of interdigital neuroma, excessive pain and tenderness during mobility. 4. Foot posture in advanced pronation or supination. 5. The presence of diseases or problems that may affect gait (necessity of using a walking aid, visual or hearing impairment, other problems related to the lower extremity or spine). 6. Having experienced orthopedic trauma or surgery involving the lower extremity. 7. The presence of severe shortness of breath or inability to tolerate walking while walking. 8. The person's; 9. Having a medical history that increases the risk of falls, such as unexplained fainting, blood sugar imbalance, unstable low or high blood pressure. 10\. Having an orthopedic or rheumatological disease (rheumatoid arthritis, gout, etc.) or a systemic disease associated with diabetes or connective tissue disorder. 11\. Being pregnant or in the first 6 months postpartum. 12. Having cooperation problems to the extent that one cannot understand and comply with the assessment protocols.

Primary outcome measure(s)

  • Pedobarogaphic parameters — Day 1
    Regional plantar pressure analysis (heel, midfoot, metatarsal heads and hallux)

Trial sites (1)

FacilityCityRegionStatus
Pınar Kısacık Ankara Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07409974 on ClinicalTrials.gov ↗ ← All trials in Turkey